Oncotelic
Press Releases
All press releases, organized by date
We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable TGF-beta therapeutics to realize their true potential and to bring much needed new therapies for orphan indications to patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need including rare pediatric indication and COVID-19/zoonoses that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “OTLC”.
Click HERE for Litchfield Hills Research analyst report OTLC-Reiterate Buy and $4 PT- 8/25/2022.
Click HERE for Litchfield Hills Research analyst report OTLC-Reiterate Buy and $4 PT- 3/31/2022.
Click HERE for Litchfield Hills Research analyst report OTLC-Buy-$4 PT – 12/6/2021.
Click HERE for Litchfield Hills Research analyst report upgrade price target to $4 from $3 – 3/3/2021.
Click HERE for Litchfield Hills Research analyst report updated – 1/6/2021.
Click HERE for Litchfield Hills Research analyst report.
Click HERE for Zacks SCR upgrade analyst report- 12/16/2020.
Click HERE for Zacks SCR analyst report.
Click HERE for Stonegate analyst report.
Click on any of the links in the left-hand sidebar for more information.
We are headquartered in Agoura Hills, California.